Rimonabant-induced Δ9-tetrahydrocannabinol withdrawal in rhesus monkeys: Discriminative stimulus effects and other withdrawal signs

Journal of Pharmacology and Experimental Therapeutics

Volumn 334, Issue 1, 2010, Pages 347-356

  Stewart, Jennifer L ^a   McMahon, Lance R ^a  

^a Mays Cancer Center at UT Health San Antonio   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; 4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; CANNABINOID; CANNABINOID RECEPTOR; CLONIDINE; COCAINE; DIAZEPAM; DRONABINOL; RIMONABANT; 3 (2 HYDROXY 4 (1,1 DIMETHYLHEPTYL)PHENYL) 4 (3 HYDROXYPROPYL)CYCLOHEXANOL; 3-(2-HYDROXY-4-(1,1-DIMETHYLHEPTYL)PHENYL)-4-(3-HYDROXYPROPYL)CYCLOHEXANOL; ADRENERGIC RECEPTOR STIMULATING AGENT; BENZOXAZINE DERIVATIVE; CYCLOHEXANOL DERIVATIVE; MORPHOLINE DERIVATIVE; NAPHTHALENE DERIVATIVE; PIPERIDINE DERIVATIVE; PYRAZOLE DERIVATIVE; TETRAHYDROCANNABINOL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DISCRIMINATIVE STIMULUS; DOSE RESPONSE; DRUG DEPENDENCE; DRUG DISCRIMINATION; DRUG WITHDRAWAL; FEMALE; HEAD SHAKING; HEART RATE; HYPERACTIVITY; LIGHT DARK CYCLE; LOCOMOTION; MALE; NONHUMAN; PRIORITY JOURNAL; RHESUS MONKEY; TACHYCARDIA; ANIMAL; ANIMAL BEHAVIOR; DRUG ANTAGONISM; DRUG EFFECT; DRUG POTENTIATION; MACACA; MOTOR ACTIVITY; PERCEPTIVE DISCRIMINATION; PSYCHOLOGICAL ASPECT; WITHDRAWAL SYNDROME;

ADRENERGIC AGONISTS; ANIMALS; BEHAVIOR, ANIMAL; BENZOXAZINES; CLONIDINE; CYCLOHEXANOLS; DISCRIMINATION (PSYCHOLOGY); FEMALE; HEART RATE; MACACA MULATTA; MALE; MORPHOLINES; MOTOR ACTIVITY; NAPHTHALENES; PIPERIDINES; PYRAZOLES; RECEPTORS, CANNABINOID; SUBSTANCE WITHDRAWAL SYNDROME; TETRAHYDROCANNABINOL;

EID: 77953772802     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.110.168435     Document Type: Article

References (33)

1. 9-tetrahydrocannabinol: studies on precipitated and abrupt withdrawal. J Pharmacol Exp Ther 278:1290-1295.
2. Beardsley PM, Balster RL, and Harris LS (1986) Dependence on tetrahydrocannabinol in rhesus monkeys. J Pharmacol Exp Ther 239:311-319.
3. Boisse NR and Okamoto M (1978) Physical dependence to barbital compared to pentobarbital. IV. Influence of elimination kinetics. J Pharmacol Exp Ther 204: 526-540. (Pubitemid 8329256)
4. Bouaboula M, Perrachon S, Milligan L, Canat X, Rinaldi-Carmona M, Portier M, Barth F, Calandra B, Pecceu F, Lupker J, et al. (1997) A selective inverse agonist for central cannabinoid receptor inhibits mitogen-activated protein kinase activation stimulated by insulin or insulin-like growth factor 1. Evidence for a new model of receptor/ligand interactions. J Biol Chem 272:22330-22339.
5. Budney AJ, Hughes JR, Moore BA, and Vandrey R (2004) Review of the validity and significance of cannabis withdrawal syndrome. Am J Psychiatry 161:1967-1977.
6. Budney AJ, Novy PL, and Hughes JR (1999) Marijuana withdrawal among adults seeking treatment for marijuana dependence. Addiction 94:1311-1322.
7. Compton WM, Grant BF, Colliver JD, Glantz MD, and Stinson FS (2004) Prevalence of marijuana use disorders in the United States: 1991-1992 and 2001-2002. J Am Med Assoc 291:2114-2121.
8. 9- tetrahydrocannabinol. J Pharmacol Exp Ther 285:1150-1156.
9. Diana M, Melis M, Muntoni AL, and Gessa GL (1998) Mesolimbic dopaminergic decline after cannabinoid withdrawal. Proc Natl Acad Sci USA 95:10269-10273.
10. Elkashef A, Vocci F, Huestis M, Haney M, Budney A, Gruber A, and el-Guebaly N (2008) Marijuana neurobiology and treatment. Subst Abus 29:17-29.
11. Emmett-Oglesby MW, Mathis DA, Moon RT, and Lal H (1990) Animal models of drug withdrawal symptoms. Psychopharmacology 101:292-309.
12. 9-terahydrocannabinol in rhesus monkeys. Psychopharmacology 71:201-202.
13. 9- tetrahydrocannabinol to rhesus monkeys. J Pharmacol Exp Ther 216:247-253.
14. Gellert VF and Holtzman SG (1979) Discriminative stimulus effects of naltrexone in the morphine-dependent rat. J Pharmacol Exp Ther 211:596-605. (Pubitemid 10183155)
15. Grotenhermen F (2003) Pharmacokinetics and pharmacodynamics of cannabinoids. Clin Pharmacokinet 42:327-360.
16. Haney M, Hart CL, Vosburg SK, Comer SD, Reed SC, and Foltin RW (2008) Effects of THC and lofexidine in a human laboratory model of marijuana withdrawal and relapse. Psychopharmacology 197:157-168.
17. Haney M, Ward AS, Comer SD, Foltin RW, and Fischman MW (1999a) Abstinence symptoms following oral THC administration to humans. Psychopharmacology 141:385-394. (Pubitemid 29190007)
18. Haney M, Ward AS, Comer SD, Foltin RW, and Fischman MW (1999b) Abstinence symptoms following smoked marijuana in humans. Psychopharmacology 141:395-404. (Pubitemid 29190008)
19. 9-tetrahydrocannabinol in rhesus monkeys. Psychopharmacologia 37:23-29.
20. 9-trans-tetrahydrocannabinol in rats. Pharmacology 12:290-295.
21. Kenakin T (1997) Pharmacologic Analysis of Drug-Receptor Interaction. Lippincott-Raven Publishers, Philadelphia, PA.
22. 9-tetrahydrocannabinol or clonidine. Pharmacol Biochem Behav 69:181-188.
23. Lichtman AH and Martin BR (2002) Marijuana withdrawal syndrome in the animal model. J Clin Pharmacol 42:20S-27S.
24. 9-tetrahydrocannabinol. Psychopharmacology 188:306-314.
25. 9-tetrahydrocannabinol. J Pharmacol Exp Ther 319:1211-1218.
26. 9-tetrahydrocannabinol. Psychopharmacology 203:219-228.
27. National Research Council (1996) Guide for the Care and Use of Laboratory Animals. National Academy Press, Washington, DC.
28. Roehrich H and Gold MS (1987) Clonidine. Adv Alcohol Subst Abuse 7:1-16.
29. Sannerud CA, Allen M, Cook JM, and Griffiths RR (1991) Behavioral effects of benzodiazepine ligands in non-dependent, diazepam-dependent, and diazepamwithdrawn baboons. Eur J Pharmacol 202:159-169.
30. Stark P and Dews PB (1980) Cannabinoids. I. Behavioral effects. J Pharmacol Exp Ther 214:124-130.
31. Tallarida RJ (2000) Drug Synergism and Dose-Effect Data Analysis, pp 44-50, Chapman and Hall/CRC, Boca Raton, FL.
32. Vandrey R and Haney M (2009) Pharmacotherapy for cannabis dependence: how close are we? CNS Drugs 23:543-553.
33. Vivian JA, Kishioka S, Butelman ER, Broadbear J, Lee KO, and Woods JH (1998) Analgesic, respiratory, and heart rate effects of cannabinoid and opioid agonists in rhesus monkeys: antagonist effects of SR 141716A. J Pharmacol Exp Ther 286: 697-703. (Pubitemid 29003458)